BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dierickx D, Beke E, Devos T, Delannoy A. The Use of Monoclonal Antibodies in Immune-Mediated Hematologic Disorders. Medical Clinics of North America 2012;96:583-619. [DOI: 10.1016/j.mcna.2012.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Minnee RC, Fieuws S, Jochmans I, Aerts R, Sainz Barriga M, Debaveye Y, Maertens J, Vandenberghe P, Laleman W, van der Merwe S, Verslype C, Cassiman D, Ferdinande P, Nevens F, Pirenne J, Monbaliu D. Improved survival after LTx-associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single-center experience and systematic review. Am J Transplant 2018;18:3007-20. [PMID: 29734503 DOI: 10.1111/ajt.14923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Novy Z, Laznickova A, Mandikova J, Barta P, Laznicek M, Trejtnar F. The effect of chelator type on in vitro receptor binding and stability in 177 Lu-labeled cetuximab and panitumumab: In vitro binding of 177 Lu-labeled cetuximab and panitumumab. J Label Compd Radiopharm 2014;57:448-52. [DOI: 10.1002/jlcr.3204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
3 Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood 2015;125:3223-9. [DOI: 10.1182/blood-2015-01-588392] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
4 Sys J, Provan D, Schauwvlieghe A, Vanderschueren S, Dierickx D. The role of splenectomy in autoimmune hematological disorders: Outdated or still worth considering? Blood Reviews 2017;31:159-72. [DOI: 10.1016/j.blre.2017.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]